TCRX Profile
TScan Therapeutics, Inc. is an emerging biopharmaceutical firm focused on developing advanced T cell receptor (TCR) engineered T cell therapies to address various forms of cancer. The company, in its preclinical stage, is pioneering the use of TCR technology to enhance the immune system's ability to target and destroy cancer cells. TScan's lead therapeutic candidates include TSC-100 and TSC-101, designed specifically for treating hematologic malignancies. These therapies aim to eliminate residual leukemia and prevent relapse following hematopoietic stem cell transplantation, representing a significant advancement in the management of blood cancers.
In addition to its work in hematologic cancers, TScan Therapeutics is advancing a series of therapies targeting solid tumors, with candidates such as TSC-200 through TSC-204 currently under development. These therapies are designed to harness the specificity of TCRs to recognize and attack cancerous cells in various solid tumors, a challenging area in oncology where precise targeting is crucial for effective treatment outcomes. The company's approach aims to overcome limitations associated with traditional cancer treatments and improve long-term patient survival.
Beyond oncology, TScan Therapeutics is also exploring vaccine development to address infectious diseases, including SARS-CoV-2, the virus responsible for COVID-19. This diversification reflects the company's commitment to leveraging its TCR technology platform to address a broader range of medical needs, enhancing its impact on public health and potentially broadening its market opportunities.
TScan Therapeutics maintains a strategic collaboration with Novartis Institutes for BioMedical Research, Inc., focusing on identifying novel cancer antigens from the T cells of patients with specific cancer types. This partnership underscores the company's commitment to innovation and the pursuit of cutting-edge solutions in cancer therapy. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics continues to advance its research and development efforts with the goal of transforming cancer treatment and improving patient outcomes on a global scale.
|
